Hiroyuki Shimada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12331/publications.pdf

Version: 2024-02-01

153 papers 11,413 citations

50170 46 h-index 29081 104 g-index

154 all docs

154 docs citations

154 times ranked 8361 citing authors

#	Article	IF	Citations
1	Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid. New England Journal of Medicine, 1999, 341, 1165-1173.	13.9	1,722
2	The International Neuroblastoma Pathology Classification (the Shimada system). Cancer, 1999, 86, 364-372.	2.0	940
3	Histopathologic Prognostic Factors in Neuroblastic Tumors: Definition of Subtypes of Ganglioneuroblastoma and an Age-Linked Classification of Neuroblastomas. Journal of the National Cancer Institute, 1984, 73, 405-416.	3.0	796
4	Terminology and morphologic criteria of neuroblastic tumors. Cancer, 1999, 86, 349-363.	2.0	583
5	Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. New England Journal of Medicine, 2005, 353, 2243-2253.	13.9	495
6	Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	298
7	International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors. Cancer, 2001, 92, 2451-2461.	2.0	273
8	Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma. New England Journal of Medicine, 2010, 363, 1313-1323.	13.9	253
9	Revision of the International Neuroblastoma Pathology Classification. Cancer, 2003, 98, 2274-2281.	2.0	249
10	Favorable Biology and Outcome of Stage IV-S Neuroblastoma With Supportive Care or Minimal Therapy: A Children's Cancer Group Study. Journal of Clinical Oncology, 2000, 18, 477-477.	0.8	243
11	Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma. Journal of Clinical Oncology, 2012, 30, 3525-3532.	0.8	236
12	Biologic Variables in the Outcome of Stages I and II Neuroblastoma Treated With Surgery as Primary Therapy: A Children's Cancer Group Study. Journal of Clinical Oncology, 2000, 18, 18-18.	0.8	218
13	Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children's Cancer Group Study. Journal of Clinical Oncology, 2000, 18, 1260-1268.	0.8	212
14	Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification. Journal of the National Cancer Institute, 2006, 98, 1193-1203.	3.0	212
15	Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641. Journal of Clinical Oncology, 2012, 30, 1842-1848.	0.8	174
16	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	0.8	174
17	Identification of Subsets of Neuroblastomas by Combined Histopathologic and N-myc Analysis. Journal of the National Cancer Institute, 1995, 87, 1470-1476.	3.0	154
18	Double Staining with Brilliant Blue G and Double Peeling for Epiretinal Membranes. Ophthalmology, 2009, 116, 1370-1376.	2.5	151

#	Article	IF	CITATIONS
19	Current Treatment Protocols Have Eliminated the Prognostic Advantage of Type 1 Fusions in Ewing Sarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2010, 28, 1989-1994.	0.8	138
20	Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study. Journal of Clinical Oncology, 2005, 23, 6474-6480.	0.8	133
21	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. Cancer, 2001, 92, 2699-2708.	2.0	132
22	Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Research, 2017, 77, 5142-5157.	0.4	130
23	25-Gauge Scleral Tunnel Transconjunctival Vitrectomy. American Journal of Ophthalmology, 2006, 142, 871-873.	1.7	125
24	Incidence of Endophthalmitis after 20- and 25-Gauge Vitrectomy. Ophthalmology, 2008, 115, 2215-2220.	2.5	122
25	Critical Role of STAT3 in IL-6–Mediated Drug Resistance in Human Neuroblastoma. Cancer Research, 2013, 73, 3852-3864.	0.4	109
26	Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Histopathologic features-A report from the children's cancer group. Medical and Pediatric Oncology, 2001, 36, 623-629.	1.0	105
27	Mouse Mesenchymal Stem Cells Expressing PAX-FKHR Form Alveolar Rhabdomyosarcomas by Cooperating with Secondary Mutations. Cancer Research, 2008, 68, 6587-6597.	0.4	102
28	Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer, 2017, 123, 4224-4235.	2.0	97
29	Human and mouse tissue-engineered small intestine both demonstrate digestive and absorptive function. American Journal of Physiology - Renal Physiology, 2015, 308, G664-G677.	1.6	88
30	Malignant rhabdoid tumor. A study with two established cell lines. Cancer, 1993, 71, 2862-2872.	2.0	85
31	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nature Communications, 2021, 12, 511.	5.8	85
32	Expanded Indications for 25-Gauge Transconjunctival Vitrectomy. Japanese Journal of Ophthalmology, 2005, 49, 397-401.	0.9	82
33	Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. Pediatric Blood and Cancer, 2009, 53, 563-569.	0.8	79
34	Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer, 2017, 123, 1095-1105.	2.0	75
35	Minimizing the endophthalmitis rate following intravitreal injections using 0.25Â% povidone–iodine irrigation and surgical mask. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 1885-1890.	1.0	71
36	JC virus detection by in situ hybridization in brain tissue from elderly patients. Annals of Neurology, 1991, 29, 428-432.	2.8	70

#	Article	IF	Citations
37	Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. Clinical Cancer Research, 2012, 18, 2679-2686.	3.2	69
38	Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. Cancer, 2013, 119, 3718-3726.	2.0	67
39	Dose Escalation Study of No-Carrier-Added ¹³¹ I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial. Journal of Nuclear Medicine, 2012, 53, 1155-1163.	2.8	64
40	International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. European Journal of Cancer, 2006, 42, 1113-1119.	1.3	63
41	Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clinical Cancer Research, 2015, 21, 2715-2721.	3.2	62
42	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 3243-3255.	0.8	61
43	Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma:ÂA study from the International Neuroblastoma Risk Group database. European Journal of Cancer, 2016, 65, 1-10.	1.3	56
44	Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. Japanese Journal of Ophthalmology, 2008, 52, 282-288.	0.9	55
45	Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells. Clinical Cancer Research, 2019, 25, 4761-4774.	3.2	53
46	Concentration Gradient of Vascular Endothelial Growth Factor in the Vitreous of Eyes with Diabetic Macular Edema., 2009, 50, 2953.		51
47	Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6097-6102.	3.3	50
48	Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. Cancer, 2002, 94, 1574-1583.	2.0	49
49	Large cell neuroblastoma. Cancer, 2004, 100, 390-397.	2.0	49
50	Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular. Cancer, 2000, 89, 1150-1161.	2.0	47
51	Contribution of neuroblastomaâ€derived exosomes to the production of proâ€tumorigenic signals by bone marrow mesenchymal stromal cells. Journal of Extracellular Vesicles, 2017, 6, 1332941.	5 . 5	47
52	Matrix Metalloproteinases and Their Inhibitors in Tumor Progression. Annals of the New York Academy of Sciences, 1994, 732, 222-232.	1.8	45
53	Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 115-124.	0.8	45
54	Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC. Oncotarget, 2017, 8, 91516-91529.	0.8	45

#	Article	IF	CITATIONS
55	One hundred neuroblastomas detected through a mass screening system in Japan. Cancer, 1994, 74, 3223-3226.	2.0	39
56	Enlarged and prominent nucleoli may be indicative of MYCN amplification. Cancer, 2005, 103, 174-180.	2.0	38
57	Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clinical Cancer Research, 2017, 23, 5374-5383.	3.2	38
58	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Journal of Clinical Oncology, 2021, 39, 3506-3514.	0.8	38
59	Tumoral invasion in the central nervous system. Journal of Neuro-Oncology, 1993, 18, 111-121.	1.4	36
60	Pathology of peripheral neuroblastic tumors: Significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma. Pathology and Oncology Research, 2007, 13, 269-275.	0.9	36
61	Does MYCN Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study. Clinical Cancer Research, 2006, 12, 5693-5697.	3.2	35
62	Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: A Report from the Children's Oncology Group. Pediatric and Developmental Pathology, 2014, 17, 441-449.	0.5	35
63	Implantable chemotherapy-loaded silk protein materials for neuroblastoma treatment. International Journal of Cancer, 2017, 140, 726-735.	2.3	35
64	Validation of a prognostic multiâ€gene signature in highâ€risk neuroblastoma using the high throughput digital NanoString nCounterâ,,¢ system. Molecular Oncology, 2014, 8, 669-678.	2.1	32
65	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget, 2018, 9, 6416-6432.	0.8	31
66	Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy. Ophthalmology, 2016, 123, 1278-1286.	2.5	30
67	Screening for neuroblastoma in north america. Preliminary results of a pathology review from the quebec project. Cancer, 1995, 76, 2363-2371.	2.0	28
68	Combined Replenishment of miRâ€34a and letâ€7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models. Small, 2020, 16, e1906426.	5 . 2	27
69	Peripheral neuroblastic tumors with genotype–phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatric Blood and Cancer, 2013, 60, 363-370.	0.8	25
70	Association of high microvessel $\hat{l}\pm v\hat{l}^23$ and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget, 2017, 8, 52193-52210.	0.8	24
71	Frequency, source, and prevention of cotton fibers in the anterior chamber during cataract surgery. Journal of Cataract and Refractive Surgery, 2008, 34, 1389-1392.	0.7	22
72	Reduced anterior chamber contamination by frequent surface irrigation with diluted iodine solutions during cataract surgery. Acta Ophthalmologica, 2017, 95, e373-e378.	0.6	22

#	Article	IF	CITATIONS
73	Utility of Phox2b immunohistochemical stain in neural crest tumours and nonâ€neural crest tumours in paediatric patients. Histopathology, 2018, 72, 685-696.	1.6	22
74	Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. Oncolmmunology, 2021, 10, 1838140.	2.1	22
75	IMAGE ANALYSIS FOR AUTOMATED ASSESSMENT OF GRADE OF NEUROBLASTIC DIFFERENTIATION. , 2007, , .		21
76	The clinical management and outcomes of cervical neuroblastic tumors. Journal of Surgical Research, 2016, 204, 109-113.	0.8	20
77	Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts. Molecular Cancer Therapeutics, 2016, 15, 2653-2664.	1.9	20
78	Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clinical Cancer Research, 2019, 25, 6044-6051.	3.2	20
79	Surgical excision of neovascularization in retinal angiomatous proliferation. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 519-524.	1.0	18
80	REDUCTION OF VITREOUS CONTAMINATION RATE AFTER 25-GAUGE VITRECTOMY BY SURFACE IRRIGATION WITH 0.25% POVIDONE–IODINE. Retina, 2013, 33, 143-151.	1.0	18
81	Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression. Journal of Pediatric Surgery, 2019, 54, 1192-1197.	0.8	18
82	MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. Cell Death and Disease, 2020, 11, 368.	2.7	18
83	Pathology review of screening negative neuroblastomas. , 1998, 83, 575-581.		17
84	Computer-Aided Grading of Neuroblastic Differentiation: Multi-Resolution and Multi-Classifier Approach. , 2007, , .		17
85	EFFECT OF OPERATIVE FIELD IRRIGATION ON INTRAOPERATIVE BACTERIAL CONTAMINATION AND POSTOPERATIVE ENDOPHTHALMITIS RATES IN 25-GAUGE VITRECTOMY. Retina, 2010, 30, 1242-1249.	1.0	17
86	Intravitreal Injection of 1.25% Povidone Iodine Followed by Vitrectomy Using 0.025% Povidone Iodine Irrigation for Treating Endophthalmitis. Translational Vision Science and Technology, 2019, 8, 21.	1.1	15
87	Foveal avascular zone area analysis in juvenile-onset type 1 diabetes using optical coherence tomography angiography. Japanese Journal of Ophthalmology, 2020, 64, 271-277.	0.9	15
88	Histopathologic features of composite ganglioneuroblastoma. Immunohistochemical distinction of the stromal component is related to prognosis. Cancer, 1990, 65, 255-264.	2.0	14
89	Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project. European Journal of Cancer, 2012, 48, 1185-1191.	1.3	14
90	Prophylaxis for acute scleral buckle infection using 0.25Â% povidone-iodine ocular surface irrigation during surgery. International Ophthalmology, 2014, 34, 211-216.	0.6	13

#	Article	IF	CITATIONS
91	Association of heterogeneous MYCN amplification with clinical features, biological characteristicsÂand outcomes in neuroblastoma: A report from the Children's Oncology Group. European Journal of Cancer, 2020, 133, 112-119.	1.3	13
92	Cataract Surgery by Intraoperative Surface Irrigation with 0.25% Povidone–lodine. Journal of Clinical Medicine, 2021, 10, 3611.	1.0	13
93	Twenty-gauge Transconjunctival Vitrectomy. Japanese Journal of Ophthalmology, 2005, 49, 257-260.	0.9	12
94	Thermal Injury Caused by Chandelier Fiber Probe. American Journal of Ophthalmology, 2007, 143, 167-169.	1.7	12
95	Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups. Biomolecules, 2022, 12, 79.	1.8	12
96	Histologic and ultrastructural features in early and advanced phases of Zellweger spectrum disorder (infantile Refsum disease). Ultrastructural Pathology, 2018, 42, 220-227.	0.4	11
97	Rare <i>MYC</i> -amplified Neuroblastoma With Large Cell Histology. Pediatric and Developmental Pathology, 2018, 21, 461-466.	0.5	11
98	Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model. Cancer Medicine, 2020, 9, 2891-2903.	1.3	11
99	Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma. Frontiers in Immunology, 2021, 12, 650427.	2.2	11
100	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2022, 40, 4107-4118.	0.8	11
101	Depiction of the vitreous pocket by optical coherence tomography. International Ophthalmology, 2011, 31, 51-53.	0.6	10
102	Am80― <scp>GCSF</scp> synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropeniaâ€associated infection andÂmortality. EMBO Molecular Medicine, 2016, 8, 1340-1359.	3.3	10
103	Predictors of response, progressionâ€free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2018, 65, e26940.	0.8	10
104	Terminology and morphologic criteria of neuroblastic tumors. Cancer, 1999, 86, 349-363.	2.0	10
105	Stage 4S Neuroblastoma. American Journal of Surgical Pathology, 2021, 45, 1075-1081.	2.1	10
106	In Situ Neuroblastoma: An Important Concept Related to the Natural History of Neural Crest Tumors. Pediatric and Developmental Pathology, 2005, 8, 305-306.	0.5	9
107	MYCN-Dependent Expression of Sulfatase-2 Regulates Neuroblastoma Cell Survival. Cancer Research, 2014, 74, 5999-6009.	0.4	9
108	Subgrouping of Unfavorable Histology Neuroblastomas With Immunohistochemistry Toward Precision Prognosis and Therapy Stratification. JCO Precision Oncology, 2019, 3, 1-7.	1,5	9

#	Article	IF	CITATIONS
109	Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification. Journal of Pediatric Surgery, 2021, 56, 1199-1202.	0.8	9
110	Neuroblastoma Pathology and Biology. Pathology International, 1992, 42, 229-241.	0.6	8
111	Early onset of Rhegmatogenous retinal detachment after LASIK with femtosecond laser. Japanese Journal of Ophthalmology, 2009, 53, 75-76.	0.9	7
112	Relationship of Area of Soft Drusen in Retina with Cerebral Amyloid- \hat{l}^2 Accumulation and Blood Amyloid- \hat{l}^2 Level in the Elderly. Journal of Alzheimer's Disease, 2018, 62, 239-245.	1.2	7
113	Capsular bag irrigation using 0.025% povidone-iodine in balanced salt solution PLUS for the treatment of postoperative endophthalmitis. International Ophthalmology, 2018, 38, 1787-1790.	0.6	7
114	No increase in incidence of post-intravitreal injection endophthalmitis without topical antibiotics: a prospective study. Japanese Journal of Ophthalmology, 2019, 63, 396-401.	0.9	7
115	Adjuvant CD49d Blockade Eradicates Chemoresistant ALL. Blood, 2010, 116, 869-869.	0.6	7
116	A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children's Oncology Group study Journal of Clinical Oncology, 2015, 33, 10017-10017.	0.8	7
117	Safety Measures for Maintaining Low Endophthalmitis Rate after Intravitreal Anti-Vascular Endothelial Growth Factor Injection before and during the COVID-19 Pandemic. Journal of Clinical Medicine, 2022, 11, 876.	1.0	7
118	A Clinicopathological Study on the Cardiac Rupture Following Myocardial Infarction in the Aged. International Heart Journal, 1968, 9, 265-280.	0.6	6
119	Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma. Genes and Immunity, 2022, 23, 129-140.	2.2	6
120	Reducing bacterial contamination inside fluid catch bag in 25-gauge vitrectomy by use of 0.25Â% povidone-iodine ocular surface irrigation. International Ophthalmology, 2013, 33, 35-38.	0.6	5
121	Low-concentration povidone-iodine for the prevention of intraocular infections in ophthalmic surgery. Current Opinion in Ophthalmology, 2022, 33, 28-34.	1.3	5
122	Highly viscous fluid in macular holes. International Ophthalmology, 2010, 30, 319-321.	0.6	4
123	Cytologic and Ultrastructural Findings of Bronchoalveolar Lavage in Patients With Chronic Granulomatous Disease. Pediatric and Developmental Pathology, 2018, 21, 347-354.	0.5	4
124	Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma. Surgery, 2020, 167, 969-977.	1.0	4
125	Three-dimensional depiction of the vitreous pocket using triamcinolone acetonide. European Journal of Ophthalmology, 2009, 19, 1102-5.	0.7	4
126	Bilateral Pachychoroid disease with type 3 Uveal effusion syndrome in one eye and central serous Chorioretinopathy in contralateral eye: a case report. BMC Ophthalmology, 2022, 22, 91.	0.6	4

#	Article	IF	CITATIONS
127	One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy. Journal of Clinical Medicine, 2022, 11, 2175.	1.0	4
128	Clear Visualization of Anterior Vitreous Incarceration into Cannulae during 25-Gauge Vitrectomy in Eyes with Asteroid Hyalosis. European Journal of Ophthalmology, 2012, 22, 293-295.	0.7	3
129	Re: Merani etÂal.: Aqueous chlorhexidine for intravitreal injection antisepsis (Ophthalmology.) Tj ETQq1 1 0.7843	14 rgBT /0 2.5	Dyerlock 10
130	International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors., 2001, 92, 2451.		3
131	Bimanual anterior vitrectomy using a 25-gauge high-speed cutter to manage vitreous loss during phacoemulsification. International Ophthalmology, 2009, 29, 253-255.	0.6	2
132	Capsular bag irrigation using 0.025% povidone-iodine in balanced salt solution PLUS for the treatment of postoperative endophthalmitis. International Ophthalmology, 2018, 38, 2267-2268.	0.6	2
133	Pioneer in Pediatric Pathology: William A (Bill) Newton Jr (1923–). Pediatric and Developmental Pathology, 2019, 22, 91-97.	0.5	2
134	Large cell neuroblastoma – Phenotypical variant of MYC-driven neuroblastoma: Report of 2 cases with different molecular characteristics. Human Pathology: Case Reports, 2021, 24, 200493.	0.2	2
135	The International Neuroblastoma Pathology Classification (the Shimada system). , 1999, 86, 364.		2
136	Pathology of Peripheral Neuroblastic Tumors. Clinical Pediatric Hematology-Oncology, 2020, 27, 73-86.	0.0	2
137	Transient increase in macular edema following vitrectomy for retinal branch vein occlusion. International Ophthalmology, 2009, 29, 95-98.	0.6	1
138	Replicating and identifying large cell neuroblastoma using high-dose intra-tumoral chemotherapy and automated digital analysis. Journal of Pediatric Surgery, 2019, 54, 2595-2599.	0.8	1
139	Age Inherently Links to Histology to Define Histoprognostic Classification of Peripheral Neuroblastic Tumors. Journal of Clinical Oncology, 2020, 38, 3719-3720.	0.8	1
140	Changes in ctDNA levels after MIBG therapy in patients with relapsed or refractory neuroblastoma Journal of Clinical Oncology, 2021, 39, 10012-10012.	0.8	1
141	A case of bilateral pachychoroid disease: polypoidal choroidal vasculopathy in one eye and peripheral exudative hemorrhagic chorioretinopathy in contralateral eye. BMC Ophthalmology, 2021, 21, 320.	0.6	1
142	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors., 2001, 92, 2699.		1
143	Neuroblastoma or not neuroblastoma. Human Pathology, 2014, 45, 662-663.	1.1	O
144	The Role of the Clinical Laboratory in the Diagnosis of Neuroblastoma. journal of applied laboratory medicine, The, 2020, 5, 254-256.	0.6	0

#	Article	IF	CITATIONS
145	A unique composite tumour of the adrenal gland in a paediatric patient, with adrenal cortical and neural crest cell-like components. Pathology, 2021, 53, 668-670.	0.3	0
146	Outcome analysis of non-high-risk neuroblastoma patients enrolled on Children's Oncology Group trials P9641 and A3961 Journal of Clinical Oncology, 2012, 30, 9533-9533.	0.8	0
147	Effect of insulin-like growth factor 2 gene expression on pleuropulmonary blastoma and embryonal rhabdomyosarcoma Journal of Clinical Oncology, 2012, 30, 9564-9564.	0.8	0
148	Genome-based outcome prediction in <i>MYCN </i> nonamplified high-risk neuroblastoma Journal of Clinical Oncology, 2012, 30, 9534-9534.	0.8	0
149	Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) to predict outcome in patients with stage 4 disease: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database Journal of Clinical Oncology, 2013, 31, 10015-10015.	0.8	0
150	Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium Journal of Clinical Oncology, 2016, 34, 10556-10556.	0.8	0
151	Abstract 1293: MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. , 2020, , .		0
152	Intraocular lens implantation and vitrectomy using 0.025% povidone-iodine in irrigation solution for bleb-related endophthalmitis. International Journal of Ophthalmology, 2020, 13, 1499-1502.	0.5	0
153	Composite Neuroblastoma Metastatic to a Lymph Node: The Novel Histopathologic Diagnosis of a Unique Multiclonal Neoplasm. Annals of Clinical and Laboratory Science, 2021, 51, 573-579.	0.2	0